Indonesia says to secure Sinopharm Covid-19 vaccine for private use

Indonesia says to secure Sinopharm Covid-19 vaccine for private use
Indonesia says to secure Sinopharm Covid-19 vaccine for private use

Hello and welcome to the details of Indonesia says to secure Sinopharm Covid-19 vaccine for private use and now with the details

Nevin Al Sukari - Sana'a - A healthcare worker wearing protective gear collects a swab sample to be tested for the coronavirus disease (Covid-19), at a local health facility in Jakarta September 29, 2020. — Reuters pic

Subscribe to our Telegram channel for the latest updates on news you need to know.


JAKARTA, Feb 25 — Indonesia will receive at least two million doses of a coronavirus vaccine produced by China’s Sinopharm for use in a private vaccination scheme due to run alongside a national inoculation programme, a minister said on Thursday.

Indonesia, which has faced one of the biggest Covid-19 outbreaks in Asia, aims to vaccinate 181.5 million people within about a year using vaccines made by companies such as Sinovac Biotech, Novavax and AstraZeneca.

Luhut Binsar Pandjaitan, Indonesia’s minister for maritime affairs and investment, said the China National Pharmaceutical Group (Sinopharm) vaccine would be part of the private scheme.

“What’s fixed is two million (doses). Three million is our hope...we will vaccinate employees in stages,” he told an economic forum.

The private plan has been pushed by Indonesian business as a way for companies to buy vaccines from the government so that their employees can be vaccinated in order to help prop up the country’s battered economy.

The private plan is due to use alternative vaccines from the ones currently being used and the government is preparing a regulation.

Bambang Heriyanto, corporate secretary of Bio Farma, a state-owned pharmaceutical company in charge of procuring vaccines, said talks were still ongoing with Sinopharm and the vaccine needed approval from the food and drugs agency (BPOM).

BPOM did not respond to a request for comment.

At the same forum, State-owned enterprises minister Erick Thohir said more than 6,600 companies had signed up for the private scheme, which some health experts have criticised because of concern it could worsen vaccine inequity.

Sinopharm did not immediately respond to a request for comment.

Sinopharm affiliate, the Wuhan Institute Of Biological Products, said on Wednesday its vaccine had an efficacy rate of 72.51 per cent against Covid-19, citing interim analysis of late-stage clinical trial data, without offering more details. — Reuters

These were the details of the news Indonesia says to secure Sinopharm Covid-19 vaccine for private use for this day. We hope that we have succeeded by giving you the full details and information. To follow all our news, you can subscribe to the alerts system or to one of our different systems to provide you with all that is new.

It is also worth noting that the original news has been published and is available at Malay Mail and the editorial team at AlKhaleej Today has confirmed it and it has been modified, and it may have been completely transferred or quoted from it and you can read and follow this news from its main source.

PREV AIDS and Corona mutations.. Researchers explain the “worrying relationship”
NEXT Pope visits divided Cyprus, eyes on migrants